Literature DB >> 20179425

5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Alain Beck1, Janice M Reichert, Thierry Wurch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20179425      PMCID： PMC2840230          DOI： 10.4161/mabs.2.2.11302

Source DB:  PubMed          Journal:  MAbs        ISSN： 1942-0862            Impact factor:   5.857


× No keyword cloud information.
  87 in total

Review 1.  Engineered protein inhibitors of proteases.

Authors:  Andrew E Nixon; Clive R Wood
Journal:  Curr Opin Drug Discov Devel       Date:  2006-03

Review 2.  Monoclonal antibodies as innovative therapeutics.

Authors:  Janice M Reichert
Journal:  Curr Pharm Biotechnol       Date:  2008-12       Impact factor: 2.837

3.  Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.

Authors:  Rafael Ponce; Leslie Abad; Lakshmi Amaravadi; Thomas Gelzleichter; Elizabeth Gore; James Green; Shalini Gupta; Danuta Herzyk; Christopher Hurst; Inge A Ivens; Thomas Kawabata; Curtis Maier; Barbara Mounho; Bonita Rup; Gopi Shankar; Holly Smith; Peter Thomas; Dan Wierda
Journal:  Regul Toxicol Pharmacol       Date:  2009-04-02       Impact factor: 3.271

Review 4.  Development of biosimilars--pharmacokinetic and pharmacodynamic considerations.

Authors:  Yow-Ming C Wang; Andrew T Chow
Journal:  J Biopharm Stat       Date:  2010-01       Impact factor: 1.051

Review 5.  When binding is enough: nonactivating antibody formats.

Authors:  Aran F Labrijn; Rob C Aalberse; Janine Schuurman
Journal:  Curr Opin Immunol       Date:  2008-07-09       Impact factor: 7.486

Review 6.  Optimization of Fc-mediated effector functions of monoclonal antibodies.

Authors:  William R Strohl
Journal:  Curr Opin Biotechnol       Date:  2009-11-04       Impact factor: 9.740

7.  Optimization of humanized IgGs in glycoengineered Pichia pastoris.

Authors:  Huijuan Li; Natarajan Sethuraman; Terrance A Stadheim; Dongxing Zha; Bianka Prinz; Nicole Ballew; Piotr Bobrowicz; Byung-Kwon Choi; W James Cook; Michael Cukan; Nga Rewa Houston-Cummings; Robert Davidson; Bing Gong; Stephen R Hamilton; Jack P Hoopes; Youwei Jiang; Nam Kim; Renee Mansfield; Juergen H Nett; Sandra Rios; Rendall Strawbridge; Stefan Wildt; Tillman U Gerngross
Journal:  Nat Biotechnol       Date:  2006-01-22       Impact factor: 54.908

Review 8.  Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.

Authors:  P Y Muller; F R Brennan
Journal:  Clin Pharmacol Ther       Date:  2009-01-28       Impact factor: 6.875

Review 9.  Rilonacept in the treatment of chronic inflammatory disorders.

Authors:  Michael F McDermott
Journal:  Drugs Today (Barc)       Date:  2009-06       Impact factor: 2.245

10.  High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.

Authors:  D M Fishwild; S L O'Donnell; T Bengoechea; D V Hudson; F Harding; S L Bernhard; D Jones; R M Kay; K M Higgins; S R Schramm; N Lonberg
Journal:  Nat Biotechnol       Date:  1996-07       Impact factor: 54.908
View more
  7 in total

Review 1.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

2.  6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.

Authors:  Alain Beck; Thierry Wurch; Janice M Reichert
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

3.  Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions.

Authors:  Sandeep Kumar; Satish K Singh; Xiaoling Wang; Bonita Rup; Davinder Gill
Journal:  Pharm Res       Date:  2011-03-25       Impact factor: 4.200

4.  Disulfide scrambling in IgG2 monoclonal antibodies: insights from molecular dynamics simulations.

Authors:  Xiaoling Wang; Sandeep Kumar; Satish K Singh
Journal:  Pharm Res       Date:  2011-06-14       Impact factor: 4.200

5.  Antibody-drug conjugates: present and future.

Authors:  Alain Beck; Janice M Reichert
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

6.  Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.

Authors:  Neil R Michaud; Jitesh P Jani; Stephen Hillerman; Konstantinos E Tsaparikos; Elsa G Barbacci-Tobin; Elisabeth Knauth; Henry Putz; Mary Campbell; George A Karam; Boris Chrunyk; David F Gebhard; Larry L Green; Jinghai J Xu; Margaret C Dunn; Tim M Coskran; Jean-Martin Lapointe; Bruce D Cohen; Kevin G Coleman; Vahe Bedian; Patrick Vincent; Shama Kajiji; Stefan J Steyn; Gary V Borzillo; Gerrit Los
Journal:  MAbs       Date:  2012-09-24       Impact factor: 5.857

7.  Biosimilar, biobetter and next generation therapeutic antibodies.

Authors:  Alain Beck
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.